55 results about "Reduced serum uric acid" patented technology

Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).

Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).

The present invention relates to a celery seed extract, a preparation and a preparation method thereof. The preparation method comprises: taking dried celery seeds, and carrying out reflux extraction 1-2 times with 2-4 times the volume of an ethanol aqueous solution with a volume fraction of 95%; collecting the extraction liquids, and carrying out pressure reducing concentration to obtain a thick extract; suspending the thick extract in water having the volume 0.5-1 time the volume of the raw material, extracting 2-4 times with an extraction reagent, and combining the organic phases after completing the extracting to obtain a crude extract; weighing silica gel having the mass of 35-55 times the mass of the crude extract, activating for 1 h at a temperature of 130 DEG C, and loading into a chromatography column; taking the crude extract, and injecting in a concentration of 0.2-0.5 g / ml; and carrying out gradient elution with petroleum ether-dichloromethane-ethyl acetate, collecting the flow, and carrying out pressure reducing concentration to obtain the celery seed extract. According to the present invention, the preparation method has characteristics of simple preparation process, less extraction number, and high yield; and the obtained celery seed extract has the good serum uric acid lowering effect.

The invention provides functional beverage containing spirulina and skipjack bone extractive. The preparation method of the beverage comprises the steps of mixing spirulina and skipjack bone extractive, performing enzymolysis to the mixture through bromelain, coating enzymatic hydrolysate through beta-cyclodextrin, and then adding other adjuvant, so as to form the beverage. The beverage not only removes algae fishy smell of spirulina, has good mouthfeel and is easy to absorb, but also can effectively reduce the serum urate level, and is small in untoward effect.

The invention provides an application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases. Provided evidences indicate that the Erding granules have new application of obviously preventing and treating hyperuricemia and gout diseases. The Erding granules are disclosed to have obvious hypouricemic effect, so as to reduce serum uric acid values of hyperuricemia and gout diseases and alleviate clinical symptoms of patients with gout.

A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

The invention discloses an application of elaeagnus conferta roxb, namely the application of the elaeagnus conferta roxb in preparation of drugs for treating kidney stones, gall-stone and hyperuricemia. In the treatment of the kidney stones, the drug is used for reducing the rate of the kidney stones, improving kidney coefficient, reducing calcium content of the kidney, reducing serum urea nitrogen and reducing serum creatinine. In the treatment of the gall-stone, the elaeagnus conferta roxb is used for treating bile pigment gallstones and cholesterol gallstones; preferably in the treatment of bilirubin gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones, calcium ion content in bile, total bilirubin concentration and free bilirubin concentration in the treatment of the bile pigment gallstones; in the treatment of the cholesterol gallstones, the elaeagnus conferta roxb is used for reducing the rate of the gallbladder stones and the cholesterol content in the bile; and in the treatment of hyperuricemia, the elaeagnus conferta roxb is used for reducing uric acid content in serum. The application of the elaeagnus conferta roxb can be spread to related products of the elaeagnus conferta roxb; and the related product includes a fruit aqueous extract of the elaeagnus conferta roxb, dewatered elaeagnus conferta roxb, capsules, troches, granulas, fruit vinegar, jam and fruit juice.

The invention relates to a preparation method and an application of kelp extract for effectively reducing uric acid, and belongs to the technical field of biological medicines. The preparation method particularly includes the steps: soaking dried kelps in 4 DEG C distilled water for 24-36 hours; draining and shearing the kelps; adding ethyl alcohol according to the mass-volume ratio of 1:6-10; sufficiently homogenizing the ethyl alcohol; stirring and soaking the kelps at the temperature of 4 DEG C for 48-72 hours after ultrasonic treatment; pumping filter liquor to 1 / 3 volume in vacuum; performing ultra-filtration concentration and vacuum freeze-drying to obtain the uric acid reducing kelp extract. By the aid of the kelp extract, the expression level of urate decorporation genes UAT can be remarkably improved, the expression level of urate reabsorption genes URAT can be reduced, and the content of serum uric acid is remarkably reduced on the premise of protecting renal functions.

The invention discloses a teabag for preventing and treating gout. The teabag is prepared through the following raw materials in parts by weight: 6-12 parts of astragalus membranaceus, 6-12 parts of pueraria lobate, 6-12 parts of gynostemma pentaphylla, 4-10 parts of poria cocos, 1-5 parts of pseudo-ginseng, 0.5-2 parts of cordyceps militaris, and 2-8 parts of green tea. The teabag is capable of promoting urate excretion, reducing serum uric acid level, and preventing and treating gout, and is fast to take effect; gout is not liable to reoccur.

Problem: Providing a composition with an action of decreasing uric acid level in human sera from a residue from distillation of distilled spirits from barley as a material having been disposed so far despite no safety problem, by a simple treatment method suitable for practical industrial-scale production without any complex purification step.Means for Solving the Problem: A serum uric acid level-decreasing agent containing as the active ingredient a component from barley subjected to fermentation, preferably a residue from distillation of distilled spirits from barley, or a liquid fraction (residual solution from distillation of distilled spirits from barley) obtained by subjecting the residue from distillation of distilled spirits from barley to a separation procedure to a solid fraction and the liquid fraction, and / or a composition obtained by fractionating the residual solution from distillation of distilled spirits from barley, which is preferably a pharmaceutical agent for the prophylaxis or therapeutic treatment of diseases requiring the decrease of serum uric acid level. A composition containing the serum uric acid level-decreasing agent is in a form of foods and drinks, pharmaceutical products and quasi-pharmaceutical products, or feeds. Foods and drinks with a label telling that the foods and the drinks are used for the prophylaxis of diseases requiring the decrease of serum uric acid level, preferably functional foods and drinks, foods and drinks as nutritious supplements or healthy foods and drinks, for decreasing serum uric acid level.

The invention relates to the field of pharmaceutical chemistry, and discloses mangiferin aglycone crystal forms I and II, and a pharmaceutical composition, preparation method and application thereof. The mangiferin aglycone crystal form I or crystal form II provided by the invention has the advantages of single crystal form, high purity, high stability, high solubility and high bioavailability, can lower the serum uric acid concentration, and can be used for preparing medicines for preventing and treating hyperuricemia. The preparation method of the mangiferin aglycone crystal form I or crystal form II has the advantages of accessible raw materials and low production cost, and is suitable for industrial production.

The invention discloses a broiler chicken low-protein feed suitable for heat stress and application of the broiler chicken low-protein feed, and belongs to the field of animal husbandry and feed. Thecrude protein content in the feed can be reduced by 4-4.5% compared with the feeding standard, the feed is prepared on the basis of an ideal amino acid mode, and cystine, glycine and other crystallineamino acids are added. The broiler chicken low-protein feed can overcome the defect of poor broiler chicken feeding effect of low-protein daily ration in summer heat stress ubiquitous in the industry. Under a heat stress condition, after broiler chickens are fed with the feed, the weight gain can be remarkably improved, the feed efficiency can be improved, the pectoral muscle rate can be increased, and the serum uric acid level can be reduced. The feed not only can save protein feed and improve the utilization rate of nitrogen, but also can ensure that the broiler chickens can obtain the growth performance and carcass composition which are equal to or superior to those of a normal feed, and has remarkable ecological benefits and good application prospects.

The invention belongs to the field of medicinal chemistry, and relates to an application of oridonin in preparation of drugs for treating hyperuricemia and resisting gout. The invention provides a newapplication of oridonin as a unique effective component or a main effective component in preparation of drugs for treating hyperuricemia and resisting gout. The application amount of oridonin in miceis intragastric administration according to 10 mg / kg body weight, and oridonin can reduce the serum uric acid level after administration, inhibits the xanthine oxidase activity in liver tissues, produces the effects of treating hyperuricemia and resisting gout, and has the advantages of small dosage, no obvious toxicity to liver and kidney, and the like. The invention opens up a new application of oridonin, and provides a new direction for improving the phenomenon of large side effects of existing drugs for resisting gout.

The invention provides an application of olsalazine sodium in preparation of medicines for preventing and treating hyperuricemia and gout. The olsalazine sodium obviously inhibits the activity of xanthine oxidase in vitro, has IC50 of 9.8mu mol / L, and is a hybrid type xanthine oxidase inhibitor. The in vivo study shows that intraperitoneal injection of the 5.0mg / kg compound obviously reduces the level of serum uric acid of an oteracil potassium induced hyperuricemia mouse, and the dosage for reducing serum uric acid is very less than the dosage for treating ulcerative colitis clinically; and the olsalazine sodium has the characteristics of high efficiency and low toxicity and can be used for preparing medicines and health products for preventing and treating hyperuricemia and gout.

The invention relates to the field of medicinal chemistry and discloses crystal forms I and II of mangiferin aglycon and pharmaceutical compositions, preparation methods and application of the crystal forms I and II. The crystal form I or II of mangiferin aglycon disclosed by the invention is single, high in purity, high in stability and high in solubility and bioavailability, is capable of reducing the concentration of a serum uric acid, and can be used for preparing drugs for preventing and treating hyperuricemia. The preparation method for the crystal form I or II of mangiferin aglycon disclosed by the invention is simple to operate, is easy to obtain raw materials, are low in production cost and is suitable for industrial production.

The invention discloses application of centipede and pseudo-ginseng extract in preparation of a medicine for treating gout and a pharmaceutical composition of the centipede pseudo-ginseng extract. The centipede pseudo-ginseng extract contains centipede and pseudo-ginseng total saponin and is prepared by adopting a water decocting method. Pharmacological testing and clinical test prove that the centipede and pseudo-ginseng extract has a good effect for treating gout and has the advantages of high efficiency and low toxicity. The centipede and pseudo-ginseng extract has the effect of reducing serum uric acid level in a rat suffering from hyperuricemia, and the treatment effect is played without adopting the means of inhibiting expression of xanthine oxidase. The centipede and pseudo-ginseng extract has the effect of reducing the serum uric acid level in a mouse suffering from hyperuricemia.

Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.